Michal Vrablik Selected Research

Michal Vrablik Research Topics

Disease

9	Atherosclerosis 05/2022 - 01/2011
7	Cardiovascular Diseases (Cardiovascular Disease) 09/2022 - 08/2008
5	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2022 - 05/2011
4	Inflammation (Inflammations) 01/2022 - 01/2011
4	Muscular Diseases (Myopathy) 01/2022 - 01/2012
3	Myocardial Infarction 01/2022 - 01/2003
3	Type 2 Diabetes Mellitus (MODY) 01/2022 - 05/2013
3	Dyslipidemias (Dyslipidemia) 10/2019 - 01/2011
3	Myalgia 12/2017 - 01/2012
2	Hypertension (High Blood Pressure) 01/2022 - 01/2021
2	Diabetes Mellitus 01/2021 - 05/2013
2	Thromboembolism 01/2008 - 10/2006
1	Rheumatoid Arthritis 09/2022
1	Multiple Sclerosis 06/2022
1	Myositis (Idiopathic Inflammatory Myopathies) 01/2022
1	Heart Failure 01/2022
1	Polymyositis 01/2022
1	Dermatomyositis (Dermatopolymyositis) 01/2022
1	Tachycardia (Tachyarrhythmias) 01/2022
1	Rheumatic Diseases (Rheumatism) 01/2022
1	Vascular Diseases (Vascular Disease) 12/2021
1	Acute Coronary Syndrome 01/2021
1	Virus Diseases (Viral Diseases) 01/2020
1	Infections 01/2020
1	COVID-19 01/2020
1	Skeletal Abnormalities Mandibular Hypoplasia Auditory Canal Atresia Short Stature 12/2017
1	Injection Site Reaction 01/2017
1	Unstable Angina 01/2017
1	Stroke (Strokes) 01/2017
1	Coronary Artery Disease (Coronary Atherosclerosis) 05/2013
1	Osteoporosis 01/2012
1	Coronary Disease (Coronary Heart Disease) 01/2012
1	Atrophy 01/2012
1	Hypercholesterolemia 01/2011
1	Body Weight (Weight, Body) 01/2011
1	Overweight 01/2011
1	Frailty 01/2011
1	Weight Loss (Weight Reduction) 01/2011

Drug/Important Bio-Agent (IBA)

11	LipidsIBA 09/2022 - 04/2016
8	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2021 - 01/2011
6	oxidized low density lipoproteinIBA 05/2022 - 04/2016
3	CholesterolIBA 06/2022 - 01/2011
3	Triglycerides (Triacylglycerol)IBA 01/2021 - 01/2003
2	LDL CholesterolIBA 05/2022 - 01/2021
2	Lipoproteins (Lipoprotein)IBA 01/2022 - 01/2011
2	Fenofibrate (CiL)FDA LinkGeneric 01/2021 - 04/2016
2	EnzymesIBA 12/2017 - 01/2011
2	Atorvastatin (Lipitor)FDA Link 12/2017 - 01/2012
2	coenzyme Q10 (CoQ10)IBA 12/2017 - 01/2012
2	HDL CholesterolIBA 05/2013 - 05/2011
1	Glucose (Dextrose)FDA LinkGeneric 01/2022
1	Angiotensin Receptor AntagonistsIBA 01/2022
1	Apolipoprotein B-100 (Apo B 100)IBA 01/2022
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2022
1	IncretinsIBA 01/2022
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2022
1	Ligases (Synthetase)IBA 01/2022
1	Proprotein Convertase 9IBA 01/2022
1	GlucocorticoidsIBA 01/2022
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2022
1	LDL Receptors (LDL Receptor)IBA 01/2022
1	InterleukinsIBA 12/2021
1	Pharmaceutical PreparationsIBA 12/2021
1	canakinumab FDA Link 12/2021
1	Antihypertensive Agents (Antihypertensives)IBA 01/2021
1	Simvastatin (Zocor)FDA LinkGeneric 12/2017
1	bococizumabIBA 01/2017
1	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 06/2015
1	Estrogens (Estrogen)FDA Link 01/2012
1	Apolipoproteins E (ApoE)IBA 01/2011
1	Oxidoreductases (Dehydrogenase)IBA 01/2011
1	glutaryl-coenzyme A (glutaryl-CoA)IBA 01/2011
1	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 01/2011
1	lipoprotein-associated coagulation inhibitor (TFPI)IBA 10/2006
1	ApolipoproteinsIBA 01/2003

Therapy/Procedure

9	Therapeutics 01/2022 - 01/2012
3	Estrogen Replacement Therapy 08/2008 - 10/2006
2	Secondary Prevention 01/2021 - 01/2012
2	Hormone Replacement Therapy (Therapy, Hormone Replacement) 01/2012 - 08/2008
1	Cutaneous Administration 10/2006